The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma

• Published in: BMC cancer Vol. 24; no. 1; pp. 928 - 16
• Main Authors: Wu, Di, Yin, Hongli, Yang, Chun, Zhang, Zimu, Fang, Fang, Wang, Jianwei, Li, Xiaolu, Xie, Yi, Hu, Xiaohan, Zhuo, Ran, Chen, Yanling, Yu, Juanjuan, Li, Tiandan, Li, Gen, Pan, Jian
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.08.2024; BioMed Central; BMC
• Subjects: Animals; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antitumor activity; Apoptosis; Apoptosis - drug effects; Bone cancer; Bone growth; Bone Neoplasms - drug therapy; Bone Neoplasms - genetics; Bone Neoplasms - metabolism; Bone Neoplasms - pathology; Bone tumors; BRD4; Bromodomain Containing Proteins; Carcinogenesis; Care and treatment; Cell culture; Cell cycle; Cell Cycle Proteins - antagonists & inhibitors; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Cell size; Chromatin; Cloning; Development and progression; Diagnosis; Dosage and administration; Enhancer Elements, Genetic; Enhancers; Epigenetics; Flow cytometry; Gene Expression Regulation, Neoplastic - drug effects; Gene regulation; Genes; Genetic aspects; Health aspects; Humans; KRT80; Medical prognosis; Medical research; Metastases; Metastasis; Mice; Mice, Nude; Microwaves; Osteosarcoma; Osteosarcoma - drug therapy; Osteosarcoma - genetics; Osteosarcoma - metabolism; Osteosarcoma - pathology; Osteosarcoma cells; PROTAC; RNA polymerase; Sarcoma; SEs; Toxicity; Transcription Factors - antagonists & inhibitors; Transcription Factors - genetics; Transcription Factors - metabolism; Tumorigenesis; Tumors; Xenograft Model Antitumor Assays; Xenografts; China; SEs; KRT80; OS; PROTAC; BRD4
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-12691-y

Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE-987 targeting SEs in OS and preliminarily explore its mechanism. We evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE-987. We assessed the anti-tumor effect of GNE-987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP-seq with RNA-seq techniques to find its anti-tumor mechanism. In this study, we found that extremely low concentrations of GNE-987(2-10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE-987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE-987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE-987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA-seq and ChIP-seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE-987 treatment. KRT80 was identified as playing an important role in OS occurrence and development. This research revealed that GNE-987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE-987 has the potential to affect KRT80 against OS.